Toripalimab, Radiation
Conditions
Brief summary
pMMR/MSS and 32 dMMR/MSI-H patientspatients were planned to be enrolled. Patients with dMMR/MSI-H will be randomly assigned to the immunotherapy arm or short-course radiotherapy sequential immunotherapy arm; pMMR/MSS patients will receive capecitabine-irinotecan based concurrent radiotherapy before being randomly assigned to the XELIRI or FOLFRINOX arm. The rate of complete response (sustained cCR for ≥ 1 year), long-term prognosis and adverse effects will be analyzed.
Interventions
DRUGToripalimab
3mg/Kg iv d1q2w
RADIATIONCRT
IMRT 50Gy/25fx 625mg/m2 bid d1-5 qw Irinotecan:1、Full wild (GG+6/6): 80mg/m2/week for 5 times 2、Single site mutation (GG+6/7 or GA+6/6): 65mg/m2/week for 5 times 3、Double locus mutation (GG+7/7 or AA+6/6 or GA+6/7): 50mg/m2/week for the 1st, 2nd, 4th and 5th week for 4 times
RADIATIONSCRT
25Gy/5fx
DRUGXELIRI
Capecitabine: 1000mg/m2 bid d1-14 Irinotecan: 200mg/m2 ivgtt d1 q3w
DRUGFOLFRINOX
Irinotecan: 150mg/m2 ivgtt d1 (double locus mutation downregulated to 120mg/m2) Oxaliplatin: 85mg/m2 ivgtt d1 5-FU: 2400mg/m2 ivgtt 46h q2w
Sponsors
Zhejiang Cancer Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. pathological confirmed adenocarcinoma； 2. clinical stage T2-4 and/or N+，Not suitable for initial local excision to achieve radical treatment； 3. the distance from anal verge less than ≤ 5cm，or surgical evaluation concludes that direct surgical anal preservation is not possible without distance metastases； 4. age 18-70 years old, female and male； 5. Strong desire for anal preservation and ability to be closely monitored for at least 2 years after chemoradiotherapywith good compliance； 6. without distant metastases； 7. ECOG Performance status 0-1； 8. Detection of UGT1A1\*6 and \*28 gene status (for pMMR patients)； 9. Sufficient bone marrow reserve and physical capacity to receive consolidation chemotherapy after chemoradiotherapy (for pMMR patients)； 10. with good compliance； 11. signed the inform consen.
Exclusion criteria
1. pregnant or breastfeeding women； 2. Persons with a history of uncontrolled epilepsy, central nervous system disorders, or psychiatric disorders whose clinical severity, as judged by the investigator, may prevent the signing of informed consent or affect the patient's compliance with oral medications； 3. Difficult to achieve complete remission at the available level of evidence, such as: tumor largest diameter \>10 cm; largest diameter of lateral lymph nodes \>2 cm; baseline CEA \>= 100; biopsy pathology with an indolent cell carcinoma component; tumor of circumferential narrowing type on anal finger examination, with inclusion decided by the judgment of the evaluation team if necessary； 4. Clinically significant (i.e., active) heart disease, such as symptomatic coronary artery disease, New York Heart Association (NYHA) class II or worse congestive heart failure or severe arrhythmias requiring pharmacological intervention, or a history of myocardial infarction within the last 12 months； 5. persons requiring immunosuppressive therapy for organ transplantation； 6. Persons with severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases； 7. Subjects with baseline routine blood and biochemical indicators do not meet the following criteria: hemoglobin ≥ 90g/L; absolute neutrophil count (ANC) ≥ 1.5×109/L; platelets ≥ 100×109/L; ALT, AST ≤ 2.5 times the upper limit of normal; ALP ≤ 2.5 times the upper limit of normal; serum total bilirubin \< 1.5 times the upper limit of normal; serum creatinine \< 1 times the upper limit of normal limit; serum albumin ≥30g/L； 8. Known to have dihydropyrimidine dehydrogenase (DPD) deficiency； 9. allergic to any investigational drug component.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| complete response (CR) rate. | The status of cCR will be evaluated after the completion of neoadjuvant therapy. | cCR ≥ 1 year. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| QoL | From date of randomization until the date of death from any cause, assessed up to 10 years | Quality of life will be evaluated using EORTC QLQ-C30 score |
| 3 year local recurrence free survival rate | From date of randomization until the date of first documented pelvic failure, assessed up to 36 months. ] | Rate of 3 year local recurrence free survival |
| adverse effects rate. | From date of randomization until the date of death from any cause, assessed up to 5 years ] Rate of chemotherapy, radiotherapy and immunotherapy related adverse events. | CTC 4.0 standard. |
| 3 year overall survival rate | From date of randomization until the date of death from any cause, assessed up to 36 months. | Rate of 3 year overall survival |
| Organ preservation | From date of randomization until the date of surgery | TME-free survival |
| 3 year disease free survival rate | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months. ] | Rate of 3 year disease free survival |
Countries
China
Contacts
Primary ContactJI ZHU
Outcome results
None listed